Product Description
St. Jude Children's Research Hospital is developing sarcolysin as an anticancer medicine. It is a type of chemotherapy that works by slowing or stopping growth of cancer cells. It may be used to help prepare patients for hematopoietic cell transplant. (Sourced from: https://together.stjude.org/en-us/diagnosis-treatment/medicines-list/melphalan.html)
Mechanisms of Action: Alkylating Agent
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: India | Russia
Approved Indications: None
Known Adverse Events: None
Company: City of Hope Medical Center
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Ganglioneuroblastoma|Neuroblastoma|Myelodysplastic Syndrome|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Preleukemia|Acute Lymphoid Leukemia|Acute Myeloid Leukemia
Phase 2: Crohn Disease|Graft vs Host Disease|Multiple Myeloma|Paroxysmal Hemoglobinuria|Anemia, Aplastic|Lymphoma, B-Cell|Chronic Lymphoid Leukemia|Prolymphocytic T-Cell Leukemia|Lymphocytic Chronic B-Cell Leukemia|Prolymphocytic B-Cell Leukemia|Lymphoma, Non-Hodgkin|T-Cell Lymphoma|Leukemia, Plasma Cell|Prolymphocytic Leukemia|Waldenstrom Macroglobulinemia|Preleukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Burkitt Lymphoma|Acute Myelomonocytic Leukemia|Acute Myeloid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Hodgkin Lymphoma|Acute Monocytic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Myeloid Leukemia|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Blast Crisis|Myeloid, Accelerated Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia|HIV Infections|Mantle-Cell Lymphoma|Large-Cell Immunoblastic Lymphoma|Myelodysplastic Syndrome|Juvenile Myelomonocytic Leukemia,|Histiocytosis, Langerhans-Cell|Anemia, Refractory, with Excess of Blasts|Myelofibrosis|Polycythemia Vera|Thrombocythemia, Essential|Thrombocytosis|Sarcoma, Myeloid|Plasmablastic Lymphoma|Follicular Lymphoma|Neuroblastoma|Adult T-Cell Leukemia-Lymphoma|Biphenotypic Acute Leukemia|Melanoma|B-Cell Leukemia|Leukemia|Myelodysplastic-Myeloproliferative Diseases|Lymphoma|Myeloproliferative Disorders
Phase 1: Acute Monocytic Leukemia|Lymphocytic Chronic B-Cell Leukemia|Anemia, Aplastic|Acute Lymphoid Leukemia|Lymphoma, B-Cell|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Myeloid Leukemia|Neuroblastoma|Myelodysplastic Syndrome|Lymphoma, Non-Hodgkin|Blast Crisis|Chronic Myelomonocytic Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Multiple Myeloma|Chronic Lymphoid Leukemia|Leukemia, Plasma Cell|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Preleukemia|Lymphoma|Myeloproliferative Disorders|Chronic Myeloid Leukemia|Acute Myelomonocytic Leukemia|Juvenile Myelomonocytic Leukemia,|Rhabdomyosarcoma|Wilms Tumor|Adenomyoepithelioma|Rhabdoid Tumor|Sarcoma, Ewing|Gastrointestinal Cancer|Renal Cell Carcinoma|Clear Cell Sarcoma|Melanoma|Clear Cell Adenocarcinoma|Biphenotypic Acute Leukemia|Myeloid, Accelerated Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCI-2023-08530 | P3 |
Recruiting |
Ganglioneuroblastoma |
2029-12-31 |
|
| ASCT2031 | P3 |
Recruiting |
Myelodysplastic Syndrome|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Preleukemia|Acute Myeloid Leukemia|Acute Lymphoid Leukemia |
2027-12-01 |
|
| PRO11090340 | P2 |
Recruiting |
Crohn Disease |
2025-12-01 |
|
| NCI-2016-00584 | P2 |
Recruiting |
Acute Lymphoid Leukemia|B-Cell Leukemia|Multiple Myeloma|Biphenotypic Acute Leukemia|Anemia, Refractory, with Excess of Blasts|Acute Myeloid Leukemia|Myeloproliferative Disorders|Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Chronic Lymphoid Leukemia|Juvenile Myelomonocytic Leukemia,|Acute Myelomonocytic Leukemia|Myeloid, Accelerated Leukemia|Myelodysplastic-Myeloproliferative Diseases|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Lymphoma, Non-Hodgkin|Acute Monocytic Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Leukemia, Plasma Cell|Chronic Myeloid Leukemia|Lymphoma, B-Cell|Preleukemia |
2025-05-31 |